Roche Reports Topline Data from P-III (REGENCY) Trial of Gazyva/Gazyvaro (Obinutuzumab) for Treating Lupus Nephritis
Shots:
- The P-III (REGENCY) study assessed the safety & efficacy of Gazyva + standard therapy (mycophenolate mofetil & glucocorticoids) vs PBO to treat subjects (n=271) with active/chronic lupus nephritis (class III/IV)
- Study showed greater no. of patients attaining CRR and benefits were observed in 2EPs incl. CRR with reduced corticosteroid use & improved proteinuric response at 76wks.; safety aligned with the known profile, without any new concerns. Data is being shared with health authorities as well as submitted for publication & future presentation
- Gazyva is also being studied in children & adolescents with lupus nephritis, membranous nephropathy, childhood-onset idiopathic nephrotic syndrome & SLE
Ref: Roche | Image: Roche
Related News: Roche Reports Results of Gazyva (obinutuzumab) in P-II NOBILITY Study for Lupus Nephritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
